News

Hansa Biopharma announces $70 million non-dilutive product finance transaction with NovaQuest Capital Management to support continued development of the company’s antibody-cleaving enzyme technology platform across multiple therapeutic areas while extending the expected cash runway through 2024

7.18.22

TARGAN Secures $35M Series C Financing Led by Mountain Group Partners and NovaQuest Capital Management to Commercialize Novel Vaccine Delivery System for Poultry Industry

5.25.22

Phathom Pharmaceuticals Announces Revenue Interest Financing Agreement for Up to $260 Million in Non-Dilutive Capital

5.4.22

FDA Approves Mycovia Pharmaceuticals’ VIVJOA™ (oteseconazole), the First and Only FDA-Approved Medication for Recurrent Vulvovaginal Candidiasis (Chronic Yeast Infection)

4.28.22

Grünenthal and NovaQuest enter agreement to advance the resiniferatoxin global Phase III program in osteoarthritis

3.29.22

NovaQuest Capital Management Acquires TechAccel’s Interest In Covenant Animal Health Partners

11.30.21

Azurity Pharmaceuticals Completes Acquisition of Arbor Pharmaceuticals

9.20.21

Azurity Pharmaceuticals to Acquire and Merge with Arbor Pharmaceuticals

8.24.21

Dermavant Announces $200 Million of Financing

6.7.21

Mycovia Pharmaceuticals Submits New Drug Application to the U.S. FDA for Oteseconazole for the Treatment of Recurrent Vulvovaginal Candidiasis

6.1.21